Key Points
- Gilead insider Johanna Mercier sold 3,000 shares at an average price of $144.22, generating $432,660. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced her stake by 2.51% to 116,684 shares.
- Gilead reported quarterly revenue of $7.80 billion, exceeding analyst expectations of $7.40 billion, while adjusted EPS also surpassed estimates. The company declared a quarterly dividend of $0.82 per share, equivalent to a 2.2% annualized yield.
- Analysts maintain a generally positive view, with Gilead carrying a consensus “Moderate Buy” rating and an average price target of $158.78, compared with a share price of $147.68 in the article.
Gilead Sciences, Inc. (NASDAQ:GILD - Get Free Report) insider Johanna Mercier sold 3,000 shares of the stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $144.22, for a total transaction of $432,660.00. Following the completion of the transaction, the insider directly owned 116,684 shares of the company's stock, valued at approximately $16,828,166.48. The trade was a 2.51% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Johanna Mercier also recently made the following trade(s):
- On Monday, August 17th, Johanna Mercier sold 28,000 shares of Gilead Sciences stock. The shares were sold at an average price of $137.64, for a total value of $3,853,920.00.
Gilead Sciences Trading Up 0.9%
NASDAQ GILD opened at $147.68 on Thursday. The company has a market cap of $183.12 billion, a price-to-earnings ratio of -55.31 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $108.46 and a twelve month high of $157.29. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business's fifty day moving average is $139.26 and its 200 day moving average is $136.20.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. The business had revenue of $7.80 billion during the quarter, compared to analysts' expectations of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business's revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.01 EPS. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. Gilead Sciences's dividend payout ratio is currently -122.85%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have weighed in on the stock. Morgan Stanley reduced their target price on shares of Gilead Sciences from $166.00 to $165.00 and set an "overweight" rating on the stock in a report on Monday, July 27th. Maxim Group raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $165.00 price target for the company in a research note on Wednesday, May 20th. Cantor Fitzgerald reiterated an "overweight" rating and set a $155.00 price target on shares of Gilead Sciences in a report on Wednesday, August 5th. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, Wall Street Zen lowered Gilead Sciences from a "buy" rating to a "hold" rating in a research report on Saturday, September 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and a consensus target price of $158.78.
Read Our Latest Report on Gilead Sciences
Trending Headlines about Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Gilead expanded six royalty-free voluntary licensing agreements to include its investigational once-yearly lenacapavir formulation for HIV prevention. The agreements cover 120 high-incidence countries and are intended to support technology transfer, manufacturing readiness and future supply. The program could substantially broaden access to Gilead’s HIV-prevention franchise, although the formulation remains investigational. Gilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
- Positive Sentiment: A new agreement with the Pan American Health Organization will facilitate access to twice-yearly lenacapavir across PAHO member states in Latin America and the Caribbean, adding 14 countries to Gilead’s global access strategy. The deal strengthens the drug’s potential reach and supports long-term demand, though it is primarily an access initiative rather than an immediate earnings catalyst. Gilead and PAHO Announce Milestone Partnership
- Neutral Sentiment: Gilead’s $0.82-per-share dividend went ex-dividend on September 15. The payout supports the income-investment case but can create a mechanical adjustment in the share price on the ex-dividend date. Gilead Sciences Dividend Analysis
- Negative Sentiment: Chief Financial Officer Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, and each executive retained a substantial holding, limiting the negative signal for investors. CFO Insider Sale Filing
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL acquired a new position in shares of Gilead Sciences in the 4th quarter worth approximately $25,000. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the second quarter worth $25,000. Kimelman & Baird LLC bought a new position in Gilead Sciences during the second quarter worth $25,000. Wealth Preservation Advisors LLC raised its stake in Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 81 shares during the last quarter. Finally, Wiser Advisor Group LLC acquired a new position in Gilead Sciences in the second quarter valued at $30,000. Institutional investors own 83.67% of the company's stock.
About Gilead Sciences
(
Get Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company's research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.
Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
